Abivax (NASDAQ:ABVX) Stock Price Down 6.1% - Here's Why

Key Points

• Abivax shares traded down 6.1% on Thursday to about $117.43, with 1.33 million shares changing hands (a 41% decline from average volume) after a prior close of $125.01.
• Analyst sentiment is broadly positive — one Strong Buy, eleven Buy and one Sell — giving a consensus rating of Moderate Buy and a consensus price target of $135.08, with some firms (e.g., Morgan Stanley) boosting targets as high as $145.
• The company is a clinical-stage biotech (lead asset obefazimod) with a market cap of ~$8.98 billion, reported a negative EPS of ($2.46) last quarter (FY estimate -2.83) but shows strong liquidity (quick/current ratios 7.86) and very low debt-to-equity (0.03).

Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report)'s stock price traded down 6.1% during trading on Thursday . The stock traded as low as $117.01 and last traded at $117.4350. 1,329,865 shares were traded during trading, a decline of 41% from the average session volume of 2,264,633 shares. The stock had previously closed at $125.01.

Wall Street Analyst Weigh In

Several analysts have issued reports on ABVX shares. Citizens Jmp raised their price target on shares of Abivax from $114.00 to $131.00 and gave the stock a "market outperform" rating in a research report on Tuesday, December 16th. Wall Street Zen downgraded Abivax from a "hold" rating to a "sell" rating in a research report on Saturday, December 13th. Morgan Stanley upped their price target on Abivax from $101.00 to $145.00 and gave the company an "overweight" rating in a report on Friday, January 9th. JMP Securities upped their target price on shares of Abivax from $95.00 to $114.00 and gave the company a "market outperform" rating in a research note on Thursday, September 25th. Finally, Citigroup reissued a "market outperform" rating on shares of Abivax in a report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $135.08.

Abivax Price Performance

The stock has a market capitalization of $8.98 billion, a P/E ratio of -27.60 and a beta of 0.68. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. The stock has a 50-day simple moving average of $121.48 and a 200 day simple moving average of $87.48.

Abivax (NASDAQ:ABVX - Get Free Report) last issued its quarterly earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The firm had revenue of ($4.92) million during the quarter. On average, equities analysts forecast that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current fiscal year.

Institutional Trading of Abivax

A number of institutional investors and hedge funds have recently modified their holdings of ABVX. EverSource Wealth Advisors LLC raised its stake in Abivax by 4,612.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock worth $32,000 after buying an additional 369 shares during the period. First Horizon Corp acquired a new position in Abivax during the third quarter worth $36,000. Union Bancaire Privee UBP SA bought a new position in shares of Abivax in the 4th quarter valued at about $67,000. Hantz Financial Services Inc. acquired a new position in Abivax during the third quarter worth $52,000. Finally, Gordian Capital Singapore Pte Ltd acquired a new stake in Abivax in the third quarter valued at $76,000. 47.91% of the stock is owned by institutional investors.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.